Perfusion-weighted and/or diffusion-weighted MRI features have been used to predict EGFR amplification [48,49,50] and MGMT-methylation [51], whereas MR spectroscopy [52] and amino acid tracer PET imaging (FET–PET) [53] can predict IDH1 mutation status due to its effects on tumor metabolism. The gene discussed is EGFR; the disease is neoplasm.